glp 1 for eating disorders GLP-1 obesity drugs and are not well understood yet : NPR GLP-1 medications are changing medicine

For example, clinical trials of semaglutide and tirzepatide report dyspepsia occurring in approximately 3-9% of patients, with GERD and belching/eructation also noted in some product labels

Sau , c th ngh 1 thng ri tip tc s dng nu mun

In the SURMOUNT-1 study, a phase 3 clinical trial in obese patients, randomized participants in a 1:1:1:1 ratio to tirzepatide (5, 10, 15 mg) or placebo over 72 weeks, significant weight reductions were observed at 72 weeks: 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg, compared to 3.1% for placebo [18]

Navigating the Risks: When Appetite Suppression Meets Binge Eating Recovery Heres the thing, for a lot of people I see in my nutrition therapy clinic, starting a GLP-1 jabs feels like finally switching off the mental chatter around food and finally being able to go around their day and food like a normal person